Glycine
Glycine is the simplest and smallest of the 20 standard amino acids, classified as non-essential because the human body can synthesise it endogenously. However, this classification is increasingly qualified by evidence that biosynthetic capacity may be insufficient to meet the body's total glycine demand, particularly in older adults and individuals with high metabolic burden — a situation sometimes described as "conditionally essential." Glycine is the most abundant amino acid in collagen, constituting approximately one-third of its residues and stabilising the triple-helical structure; it is a precursor for glutathione, creatine, purines, haem, and porphyrins; and it functions as an inhibitory neurotransmitter in the brainstem and spinal cord. These roles have made it a focus of research in sleep, metabolic health, and ageing biology, though the clinical evidence base supporting supplementation is still early-stage.
What it is
Glycine's prevalence in collagen means that collagen-rich foods — bone broth, skin, tendons — are the primary dietary source beyond standard protein. Adults consuming typical Western diets obtain approximately 1.5 to 3 g of glycine per day from food, while estimates of total metabolic demand (accounting for collagen synthesis, glutathione production, and other biosynthetic uses) suggest a need of approximately 10 to 15 g per day, with the deficit supplied by endogenous synthesis. As endogenous glycine production declines with age and in metabolic disease, and as dietary intake from collagen-rich sources has decreased in modern diets, the case for a relative insufficiency is plausible — though whether supplementing to close this gap produces clinically meaningful benefit has not been established in adequately powered trials.
The two main mechanistic pathways generating interest in glycine supplementation are: its role as a glycine receptor agonist in the central nervous system (relevant to sleep and temperature regulation), and its role as a precursor to glutathione, the principal intracellular antioxidant whose concentrations decline with age. A third area of mechanistic interest is its involvement in one-carbon metabolism and methionine clearance, which has generated hypotheses about longevity effects in animal models.
Commercially, glycine is produced synthetically (by Ajinomoto and other manufacturers) and sold as a powder or in capsule form, typically in doses of 3 to 5 g for sleep applications. Ajinomoto SA conducted the pivotal human sleep trials for glycine, which has direct implications for interpreting those results.
What the evidence shows
Sleep. The sleep evidence for glycine is widely cited in the nutritional sleep literature but rests on a fragile, manufacturer-linked, and as yet independently unconfirmed foundation. The pivotal trials were conducted by Inagawa, Kawai, and Bannai at the Osaka Bioscience Institute between 2006 and 2012, using 3 g of glycine taken 1 hour before bed. The 2006 crossover trial (Kawai et al., Sleep and Biological Rhythms, n=11, self-reported poor sleepers) found that glycine improved subjective sleep quality and reduced daytime sleepiness. The 2007 crossover trial (Bannai et al., Sleep and Biological Rhythms, n=11) combined subjective measures with polysomnography and found improvements in sleep efficiency, reductions in time to slow-wave sleep onset, and next-day reductions in fatigue. The 2012 parallel-group trial (Bannai et al., Frontiers in Neurology, n=32, partial sleep restriction model) found improvements in daytime performance and fatigue scores. All three studies are very small, short in duration (3 to 4 nights), and all were conducted by researchers with financial relationships to Ajinomoto SA, a major glycine manufacturer. The 2024 GeroScience systematic review (Soh et al., National University of Singapore) examined glycine across eleven physiological systems and confirmed that sleep improvements in healthy populations were reported in these studies but explicitly noted small sample sizes and high risk of bias. The absence of independent replication is the primary limitation of this evidence base. No adequately powered, independently conducted, placebo-controlled trial of glycine for sleep has been published.
The proposed mechanism for the sleep effect involves glycine's inhibitory neurotransmitter activity in the suprachiasmatic nucleus and its ability to lower core body temperature via peripheral vasodilation — a mechanism shared with melatonin's sleep-promoting effects. This mechanism is biologically coherent and has preclinical support, but does not substitute for independent clinical replication.
Metabolic health. Lower plasma glycine concentrations are consistently associated with insulin resistance, obesity, non-alcoholic fatty liver disease, and type 2 diabetes in observational data. Whether this reflects a causal relationship — where glycine insufficiency drives metabolic impairment — or whether it is a consequence of metabolic dysfunction increasing glycine utilisation, remains unresolved. Several small clinical trials have found that oral glycine supplementation (typically 5 g three times daily over 3 months) reduced HbA1c, fasting blood glucose, and HOMA-IR in type 2 diabetes patients, with the most cited study by Cruz et al. reporting reductions in glycaemic markers. These trials are individually small and have not been replicated at scale. The interventional evidence for glycine-alone metabolic benefit remains much weaker than the observational and mechanistic literature, and the biological plausibility of glycine's metabolic role should not be taken as evidence that supplementation produces clinically meaningful outcomes. The current evidence does not support clinical use of glycine for glycaemic control. The Soh et al. (2024) review confirmed positive endocrine and metabolic effects in healthy populations from acute glycine boluses on insulin secretion, and in diabetic populations from longer-term supplementation, but described these findings as requiring larger and more rigorous trials before clinical conclusions can be drawn.
GlyNAC and ageing. The most striking clinical findings attributed to glycine in the longevity literature come from the GlyNAC research programme led by Rajagopal Sekhar at Baylor College of Medicine. A 2023 randomised controlled trial (Kumar et al., Journals of Gerontology, n=24 older adults and 12 young adults) found that 16 weeks of GlyNAC supplementation at 100 mg/kg/day each of glycine and N-acetylcysteine (NAC) improved glutathione deficiency, oxidative stress, mitochondrial dysfunction, insulin resistance, inflammation, physical function, and seven of nine hallmarks of ageing in older adults compared with placebo. These are striking findings from a methodologically sophisticated trial. However, GlyNAC is a combination of glycine and NAC — the effects of the combination cannot be attributed to glycine specifically. NAC is itself an established antioxidant and glutathione precursor with independent evidence. The research group's own framing — the "power of 3" combining glycine, cysteine, and glutathione — explicitly acknowledges the synergistic contribution of all three components. The trial was small, was conducted by a single research group, and requires independent replication before conclusions can be drawn about either the combination or glycine individually.
Longevity in animal models. Glycine supplementation extends lifespan in multiple animal models including C. elegans, Fisher 344 rats, and genetically heterogeneous mice. The proposed mechanism involves interaction with one-carbon metabolism and methionine restriction pathways. These findings are preclinical and cannot be extrapolated to human longevity outcomes.
Five questions
Does low status cause harm? The question of glycine insufficiency in human health is genuinely open. Low plasma glycine is associated with cardiometabolic risk, insulin resistance, and higher mortality risk in epidemiological data, and plasma glycine declines with age and obesity. Whether this is a cause or a consequence of metabolic dysfunction is not established. There is no clinical deficiency syndrome for glycine analogous to vitamin deficiencies, and whether supplementing to raise plasma glycine in people with low levels produces clinical benefit has not been formally tested in adequately powered trials.
Does supplementation prevent disease? No clinical trial evidence supports a disease-prevention claim for glycine supplementation. The associations between low plasma glycine and cardiometabolic disease are observational. Genetic variants in humans associated with higher glycine levels show reduced cardiovascular disease risk in Mendelian randomisation analyses, which provides stronger causal inference than observational association but still falls short of trial evidence for supplementation. No prevention trials have been conducted.
Does it affect biomarkers? Yes, selectively. In diabetic populations, glycine supplementation has reduced HbA1c, fasting glucose, and markers of insulin resistance in small trials. In the GlyNAC trials, glycine combined with NAC improved glutathione, oxidative stress markers, mitochondrial function markers, and multiple ageing hallmarks — though as discussed, these cannot be attributed to glycine alone. In healthy adults, a single glycine bolus improves acute insulin secretion, though the clinical significance of this is unknown. Core body temperature reduction relevant to sleep onset has been demonstrated in human studies.
Does it help clinical populations? There is limited evidence in diabetic populations showing modest glucose-lowering effects from small, older trials that have not been replicated at scale. The GlyNAC data in older adults with multiple metabolic risk factors are intriguing but attribute effects to a combination, not glycine alone. Evidence in other clinical populations is insufficient.
Does it benefit healthy individuals? The sleep evidence, while conflict-of-interest-affected and small, was generated in self-reported poor sleepers with subjective sleep complaints, which is not a clinical population but not a fully healthy one either. The studies did not examine healthy individuals without sleep complaints. Evidence of meaningful benefit in fully healthy younger adults is absent across any outcome domain in adequately powered trials.
Individual variation
Age is likely the most meaningful source of variation in glycine biology. Plasma glycine declines with age, and endogenous biosynthetic capacity may be increasingly insufficient relative to demand as collagen turnover, glutathione production needs, and methylation burden all change with ageing. If glycine insufficiency is causally relevant to any health outcome, older adults with lower circulating glycine would be the population most likely to benefit from supplementation. This hypothesis has not been directly tested in stratified trials.
Obesity and metabolic syndrome are associated with lower plasma glycine, possibly because increased metabolic demand — including higher conjugation activity to clear acylcarnitines and organic acids — increases glycine utilisation. Whether this creates a meaningful functional insufficiency amenable to supplementation is not established.
For sleep specifically, the existing trials enrolled self-reported poor sleepers. Whether people with normal sleep quality would benefit is unknown, and the mechanism — core body temperature reduction — suggests the effect may be most relevant in people with delayed or disrupted thermoregulatory sleep onset.
Sex-specific data are limited. The Kawai and Bannai sleep trials enrolled mostly or exclusively women, which limits generalisation. The GlyNAC trials included both sexes with small sample sizes, and sex-stratified analyses have not been reported.
Testing and status assessment
Plasma glycine can be measured in research settings and is available through some metabolomics panels, but no clinical reference range has been established for supplementation decision-making. Low plasma glycine is associated with metabolic disease at the population level, but its predictive value for individual supplementation response is not known. There is no clinical test that would usefully guide glycine supplementation decisions at present.
Safety
Glycine has a reassuring short-term safety profile. It is well tolerated at doses up to at least 15 g per day in published clinical trials, and doses of up to 0.8 g/kg body weight per day have been used in psychiatric populations (studies examining glycine for schizophrenia symptoms) over periods of 6 to 12 weeks without serious adverse events. At very high acute doses, nausea and gastrointestinal discomfort are reported. No significant hepatotoxicity, nephrotoxicity, or haematological abnormalities have been attributed to glycine supplementation at studied doses.
Glycine is generally recognised as safe (GRAS) by the FDA. No serious drug interactions have been documented. Theoretical interactions with clozapine and other medications in the glutamatergic system have been proposed in the context of psychiatric use, but are not relevant to typical supplemental doses used for sleep or metabolic purposes.
Long-term safety beyond 4 months has not been established in controlled trials. Pregnancy safety data are absent; given the role of glycine in foetal development and the absence of safety data, caution is appropriate.
What can reasonably be concluded
Glycine occupies an unusual position: a highly abundant amino acid with clear biological importance, a plausible set of mechanisms relevant to sleep, metabolic health, and ageing, and a commercial and marketing profile that substantially outruns its clinical evidence base. It is important to separate the evidence strands: the most direct glycine-alone clinical signal is in sleep, but it comes from a fragile, manufacturer-linked literature that remains unconfirmed by independent replication. The most striking ageing-related findings come from GlyNAC combination trials and should not be treated as glycine evidence. Metabolic effects in diabetic populations derive from small, older trials and are not established at a scale that supports clinical conclusions.
An Emerging rating reflects genuine biological plausibility and a directionally consistent early signal across multiple domains, against a background of small trials, absent independent replication, and a conflict of interest in the primary sleep evidence. The most honest summary is that the three evidence strands should be interpreted separately — glycine-alone sleep data, glycine-alone metabolic data, and GlyNAC combination data — and none is currently strong enough to support confident clinical conclusions.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.